- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02504255
Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease
Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease : A Multicenter Cohort
Crohn disease (CD) usually evolves by surges interspersed by periods of unpredictable remission. the probability of recurrence of CD in a patient in remission is even stronger if it pre-exists endoscopic lesions of the intestinal mucosa.
The mucosal healing exploration needs the realization of an ileo-colonoscopy under general anesthesia which is an invasive procedure, restrictive and expensive, thus prohibiting its too frequent repetition. we do not currently have noninvasive and reliable markers able to predict the occurrence of thrust of CD and allow the introduction of a more suitable treatment.
Indeed, relapse prevention is the best way to avoid complications and formation of lesions that lead to the irreversible medical treatment failure and surgery.
Since during the CD, it is the immunological changes that lead to inflammation and lesions, we make the assumption that the ability of certain markers immunological to predict a relapse of CD is higher than that of other in particular inflammatory markers.
This work should help to identify the profile of patients with CD in remission but at high risk of recurrence. It will specify i) the potential new markers immunological, from the pre-clinical research, predict the onset of a recurrence of CD ; ii) the predictive interest of different inflammatory markers used in routine or during the CD evaluation ; iii) Finally, the stress and the management of stressful events in the occurrence of a relapse.
This work also will specify the evolution of different markers at the moment of thrust
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Clermont-ferrand, France, 63000
- CHU Hôpital Hôtel Dieu - Service d'Hépato-Gastroentérologie
-
Pierre Benite, France, 69495
- Hospices Civils de Lyon - Groupement Hospitalier Sud - Service d'Hépato-Gastroentérologie
-
Saint-etienne, France, 42055
- CHU Hôpital Nord - Service d'Hépato-Gastroentérologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient over 18 years.
- Patient with CD previously diagnosed according to standard criteria.
- Patient remission (HBS≤4) for at least 3 months and has not received corticosteroids (including budesonide) in the 3 months before.
- Patient without concomitant treatment of Crohn's disease or as stable dose (5-ASA, corticosteroids, immunosuppressants, anti-TNF) immunosuppressants (azathioprine, Purinethol, methotrexate) and / or anti-TNF and / or 5- amino salicylates (5-ASA) for at least 6 months.
- Patient who signed a consent.
- Patient affiliated to a social security scheme.
Exclusion Criteria:
- A patient with an active CD (HB score≥5).
- Patient who relapsed in the previous three months before inclusion.
- Patient who received corticosteroids (including budesonide) in the 6 months prior to inclusion.
- Patients on stable dose of non-anti-TNF in the 6 months prior to inclusion.
- Patient taking nonsteroidal anti-inflammatory drugs or antibiotics.
- Patient with complications of intestinal sub-occlusion type fistulas or abdominal abscesses.
- Patient with exclusive perianal disease or a predominate perianal manifestation.
- Pregnant women (examination).
- Patient who is the subject of extensive intestinal resection (> 1 m).
- Patient with ileostomy or colostomy.
- Patient on legal protection measure or who does not have the legal capacity to consent
- Lack of signed written consent of the patient.-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with Crohn's Disease
patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
|
Blood, urine and faecal sampling every 3 months
patients fill several questionnaires every month to assess stress and adaptation parameters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between new immunological markers rate and Crohn's Disease relapse
Time Frame: within 15 months
|
This outcome will help us to show that regular monitoring of new immunological markers (serum markers of cytotoxicity of lymphocytes, pro- and anti-inflammatory cytokines and urinary and fecal neopterin) let us predict relapse of the disease
|
within 15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between usual immunological markers rate and Crohn's Disease relapse
Time Frame: within 15 months
|
This outcome will help us to test the ability of inflammatory markers which are already routinely used for diagnostic purposes to predict relapse of CD.
These "usual" markers are : fecal calprotectin and lactoferrin, serum ultrasensitive C-Reactive Protein (CRP) and erythrocyte sedimentation rate (ESR)) is being evaluated (serum S100A12 protein, fecal, alpha-1-glycoprotein (orosomucoid) alpha-2 globulin)
|
within 15 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010.630
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Biological samplings
-
Institut Jerome LejeuneRecruitingGenetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin (BioJeL)Intellectual Disability | Down SyndromeFrance
-
Nantes University HospitalCompletedType 1 DiabetesFrance
-
Michael J. Fox Foundation for Parkinson's ResearchUniversity Health Network, Toronto; University of Rochester; Indiana UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownCommunity Aquired PneumoniaFrance
-
Michael J. Fox Foundation for Parkinson's ResearchUniversity of Iowa; Indiana University; Banner Health; Paracelsus Elena KlinikCompleted
-
Michael J. Fox Foundation for Parkinson's ResearchUniversity Health Network, Toronto; Indiana University; ICON Clinical Research...CompletedParkinson DiseaseUnited States
-
ANRS, Emerging Infectious DiseasesViiV HealthcareCompleted
-
Michael J. Fox Foundation for Parkinson's ResearchUniversity Health Network, Toronto; University of Rochester; Indiana UniversityCompleted
-
Centre Leon BerardInternational Agency for Research on Cancer; Cancéropôle Lyon Auvergne Rhône-Alpes and other collaboratorsCompletedPesticide Poisoning
-
University Hospital OstravaRecruiting